Connect with us

Science

Digital Realty Opens Its Largest Singapore Data Center

Data center, colocation and interconnection solutions provider Digital Realty has opened its third data center in Singapore. Named SIN12, this is its largest data center in Singapore. Digital Realty (DLR)
Read More…
The post Digital Realty Opens Its…

Published

on

Data center, colocation and interconnection solutions provider Digital Realty has opened its third data center in Singapore. Named SIN12, this is its largest data center in Singapore.

Digital Realty (DLR) Chief Executive Officer, A. William Stein, said, “The opening of our third data center is a major milestone on our PlatformDIGITAL roadmap and underscores our long-term commitment to support the country’s digital economy.”

Stein added, “There is a growing need for a combination of open interconnection and next-generation collocation that will reduce the complexity of digital transformation. Expanding our footprint in Singapore will enable us to better help our customers enhance their digital transformation efforts and scale their digital business models regionally as well as globally.” (See Digital Realty stock analysis on TipRanks)

PlatformDIGITAL is Digital Realty’s global data center platform. It helps customers in scaling digital business and managing data gravity requirements by providing Pervasive Datacenter Architecture (PDx) solution methodology.

The company’s data centers are located at key metros such as Singapore, Hong Kong, Tokyo, Seoul, Melbourne and Sydney. Furthermore, it has new development projects underway in the Asia pacific (APAC) region in 2021.

Last month, Raymond James analyst Frank Louthan reiterated a Buy rating on the stock but did not assign any price target.

Commenting on the sale of legacy European data center assets to Ascendas Reit, Louthan said, “The assets are expected to generate ~$43.5 million in annualized 2021 NOI, and we believe this equates to ~17x 2021E EBITDA. Proceeds will be utilized primarily for debt repayment, a positive for shareholders as the YE’20 leverage of 6x was approaching the high end of DLR’s target range.”

Turning to the rest of the Street, the stock has a Moderate Buy consensus rating alongside an average analyst price target of $158.43 (8.7% upside potential), based on 6 Buys and 3 Holds.

Related News:
Abbott’s BinaxNOW COVID-19 Ag Self Test Cleared For Emergency Use In US
Acuity Brands Pops 13% After 2Q Earnings Beat, Sales Disappoint
United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15%

The post Digital Realty Opens Its Largest Singapore Data Center appeared first on TipRanks Financial Blog.

Read More

Continue Reading

Science

“Diamonds in the Rough” – Last Week’s Darlings and Dud

Each week in my DecisionPoint Diamonds reports, I give readers 10+ stock picks to consider. This week, we had 11 picks. I look for stocks that are beginning to show positive momentum, bullish chart patterns, breakouts and improving relative strength among

Published

on

Each week in my DecisionPoint Diamonds reports, I give readers 10+ stock picks to consider. This week, we had 11 picks. I look for stocks that are beginning to show positive momentum, bullish chart patterns, breakouts and improving relative strength among not only the SPX, but also against its industry group.

Today, I thought I would share three of last week's "Diamonds in the Rough." I have two "Darlings" and one "Dud." They aren't all winners and certainly are not "sure things," so I feel it is appropriate to show you the trade that didn't work out.

This week's "Darlings" come from the Biotech industry group, which really broke out this week. This week's "Dud" wasn't actually too bad. It was a timing issue, but it actually looks pretty good going forward. As part of a DP Diamonds subscription, you also get entrance into the Friday "Diamond Mine" where we review in detail the "Diamonds in the Rough" that presented for the week. I also take symbol requests and we look at BUY points for symbols with promise. An added bonus is that, at the end, we "mine" for new opportunities going into next week.

Below I have the "Diamonds in the Rough" as they were presented originally, followed by my comments on the chart today.

Darling #1:

Illumina, Inc. (ILMN) - Up +4.43% since 6/9


EARNINGS: 8/5/2021 (AMC)


Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Below is the chart and commentary from Wednesday (6/9):

"ILMN is down -0.01% in after-hours trading. I was surprised I hadn't covered this one before. It's not as volatile as many of the biotechs out there. We have a nice breakout from a trading range. The breakout occurred Monday and price has held above support today and yesterday. The RSI is on the overbought side, so we should be aware of that. The PMO is on an oversold BUY signal and has now reached positive territory. There was a recent IT Trend Model "Silver Cross" BUY signal when the 20-EMA crossed above the 50-EMA. The OBV is confirming the rally and the SCTR is almost in the "hot zone" above 75, meaning it is in the upper quartile among all large-cap stocks. Outperformance is clear. I like that you can set a reasonable 7% stop."

Here is today's chart:

The biggest flaw is the overbought RSI, which is flattening out. ILMN needs to consolidate Thursday's breakout. It began to today, I still love this Biotech and you can tighten the stop more too. The SCTR is now in the "hot zone" above 75, meaning it is in the top quartile among its peers in the large-cap "universe." Also, regarding the SCTR, the calculations are heavily based on intermediate- and long-term indicators.


Take advantage of our Spring special! Ending in July!

Get 50% off your first month of DecisionPoint:

Use coupon code: SAVE50 at checkout!



Arthur Hill, CMT in the free DecisionPoint Trading Room!

Arthur Hill, CMT, is the Chief Technical Strategist and main author at TrendInvestorPro.com. Schooled in classical technical analysis, Arthur crossed over to the dark side, quantitative analysis, in 2012. Classical technical analysis provides a solid foundation for learning, but is largely subjective and discretionary in nature. Quantitative analysis puts classical technical indicators to the test with clear rules, signals and results. Taken together, classical chart analysis and quantitative analysis provide the basis for Arthur's systematic approach to analysis, trading and investing. Next level technical analysis.

If you missed Arthur's appearance, here is a link to the recording:

Topic: DecisionPoint Trading Room

Start Time : Jun 7, 2021 08:41 AM

Meeting Recording Link.

Access Passcode: June-7th

Register now for the free Monday DP Trading Rooms!

Click here to register in advance for the recurring free DecisionPoint Trading Room! Recordings are available!


Darling #2:

Novavax, Inc. (NVAX) - Up +2.31% since yesterday


EARNINGS: 8/9/2021 (AMC)

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Here is the chart and commentary from Thursday (6/10):

"NVAX is up +0.16% in after hours trading. I covered NVAX as a Reader Request on July 30th, 2020. It hit its 9.2% stop when price dropped in August, so the position would be closed at this point. However, I like it today given the improvement in the Biotech space and knowing that this one is a leader based on the 98.9 SCTR. Today, price pulled back toward the breakout point. This took the RSI away from overbought territory. The PMO shows no damage and is now rising in positive territory on an oversold crossover BUY signal. Volume is coming in and, despite the pullback, the OBV didn't sustain much damage either. The stop is set below the August 2020 top."

Below is today's chart & commentary:

The trade still looks good and it isn't too late for entry. The RSI is positive and not overbought. The PMO is rising strongly on a BUY signal. Most interesting is the nearing of an IT Trend Model "Silver Cross" BUY signal, which will be triggered when the 20-EMA crossover above the 50-EMA. Join me in the free Trading Room on Monday and we'll explore the best BUY points! Register HERE if you haven't already.



Dud:


Dycom Industries, Inc. (DY) - Down -2.91% Since 6/8


EARNINGS: 8/25/2021 (BMO)


Dycom Industries, Inc. provides contracting services throughout the United States. Its services include engineering, construction, maintenance and installation services to telecommunications providers, underground facility locating services to various utilities, including other construction and maintenance services to electric and gas utilities, and others. The company was founded in 1969 and is headquartered in Palm Beach Gardens, FL.

Below is the chart and commentary from Tuesday (6/8):

"DY is up +0.72% in after hours trading. I covered DY in the October 14th 2020 Diamonds Report. I didn't put a stop on the chart, but an 8% stop wouldn't have triggered even on the big gap down in November. This means that the position is up +26.7%. The end of May was killer for DY, but it is retracing the decline rapidly. The first of two gaps has now been covered. Today's rally pushed DY above the 20-EMA. The PMO had already begun to curl upward. The RSI isn't positive yet, but it is on its way. The industry group is outperforming the SPX and DY is outperforming both. The stop is set below the gap, right around the 200-EMA at $77.28."

Below is today's chart:

While a lot of things went wrong on this chart, everything still looks bullish, especially after today's strong rally. A short-term flag has formed. The PMO had a positive crossover today. The RSI is still negative, but it is rising again. The timing was just off for it to look good this week. However, if we revisit this chart later, I expect that flag will have resolved upward and we'll be challenging the highs from April and May.

 Happy Charting! - Erin


Technical Analysis is a windsock, not a crystal ball.


Helpful DecisionPoint Links:

DecisionPoint Alert Chart List

DecisionPoint Golden Cross/Silver Cross Index Chart List

DecisionPoint Sector Chart List

DecisionPoint Chart Gallery

Trend Models

Price Momentum Oscillator (PMO)

On Balance Volume

Swenlin Trading Oscillators (STO-B and STO-V)

ITBM and ITVM

SCTR Ranking


DecisionPoint is not a registered investment advisor. Investment and trading decisions are solely your responsibility. DecisionPoint newsletters, blogs or website materials should NOT be interpreted as a recommendation or solicitation to buy or sell any security or to take any specific action.

Read More

Continue Reading

Science

EU adds another rare blood condition as side effect of AstraZeneca shot

Europe’s drug regulator on June 11 identified another rare blood condition as a potential side effect of AstraZeneca’s Covid-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.

Published

on

EU adds another rare blood condition as side effect of AstraZeneca shot

(Reuters; )

Europe’s drug regulator on Friday identified another rare blood condition as a potential side effect of AstraZeneca’s (AZN.L) COVID-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.

The European Medicines Agency’s (EMA) safety committee said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca’s vaccine, known as Vaxzevria.

People who had previously sustained the condition, where fluids leak from the smallest blood vessels causing swelling and a drop in blood pressure, should not receive the shot, the EMA added.

The regulator first began looking into these cases in April and the recommendation adds to AstraZeneca’s woes after its vaccine was associated with very rare and potentially lethal cases of blood clotting that come with a low platelet count.

Last month, the EMA had advised against using the second AstraZeneca shot for people with that clotting condition, known as thrombosis with thrombocytopenia syndrome (TTS).

The committee reviewed six validated cases of capillary leak syndrome in people, mostly women, who had received Vaxzevria, including one death. Three had had a history of the condition.

A vial of AstraZeneca coronavirus vaccine is seen at a vaccination centre in Westfield Stratford City shopping centre, amid the outbreak of coronavirus disease (COVID-19), in London, Britain, February 18, 2021. REUTERS/Henry Nicholls/File Photo

AstraZeneca declined to immediately comment.

More than 78 million Vaxzevria doses have been administered in the European Union, Liechtenstein, Iceland & Norway and Britain.

Britain’s regulator, the MHRA said on Thursday it had received 8 reports of capillary leak syndrome in the context of more than 40 million doses of the AstraZeneca vaccine given, and currently does not see a causal link.

Separately, the EMA said it was continuing its probe into cases of heart inflammation known as myocarditis and pericarditis, primarily following inoculation with the Pfizer/BioNTech (PFE.N), (22UAy.DE) and Moderna mRNA shots, but also after the J&J (JNJ.N) and AstraZeneca vaccines.

U.S. health officials said on Thursday they had registered a higher-than-expected number of heart inflammation cases in young men who received a second dose of the mRNA shots, though a causal relationship could not be established. read more

Israel’s Health Ministry said this month it had found a likely link to the condition in young men who received the Pfizer/BioNTech shot. read more

Both Pfizer and Moderna have acknowldged the observations but said a causal association with their vaccines has not been established.

BioNTech said adverse events, including myocarditis and pericarditis, are being regularly and thoroughly reviewed by the companies and regulatory authorities.

“More than 300 million doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally and the benefit risk profile of our vaccine remains positive.”

The United States and Israel have been months ahead of the EU in vaccinating men below 30, who are particularly prone to heart inflammation, giving them potentially more cases to analyse.

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/eu-advises-against-astrazeneca-shot-people-with-rare-blood-condition-2021-06-11

 

Read More

Continue Reading

Science

G7 Leaders Pledge 1 Billion Covid-19 Vaccines For Nations in Need

The summit of the Group of Seven industrialized nations in southwest England saw global leaders pledging at least 1 billion Covid-19 vaccines for underdeveloped countries and struggling nations.

Published

on

G7 Leaders Pledge One Billion COVID-19 Vaccines For Nations in Need

 

A most recent summit of the Group of Seven industrialized nations in southwest England saw global leaders pledging at least one billion COVID-19 vaccines for underdeveloped countries and struggling nations. Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.

The commitment to share these shots was announced during the session “Building Back Better From COVID-19.” During this session, President Joe Biden discussed with the G7 leaders – hailing from Canada, France, Germany, Italy, U.K. and Japan – that the U.S. will work alongside global partners to meet its goal of getting vaccines to those who need them most.

As reported by CTV News, pressure has been placed on the G7 leaders in recent months to develop a clear and workable vaccine-sharing strategy for poorer countries. The U.S., for instance, has reportedly accumulated a large stock of COVID-19 vaccines as the demand for inoculation has declined in the country.

In response, Biden said at the meeting that the U.S. plans to give up to 500 million vaccine doses to less privileged nations that currently lack widescale access. This is in addition to the 80 million doses the U.S. already committed to sharing with these countries by the end of this month. Biden also outlined a coordinated effort by each of the G7 countries to improve vaccine availability. 

British Prime Minister Boris Johnson reportedly said that 5 million does from the U.K. will be shared in the next few weeks, while the remaining vaccines will be disseminated over the next year. Johnson added that he expects the G7 leaders to commit up to 1 billion when all is said and done.

“At the G7 Summit I hope my fellow leaders will make similar pledges so that, together, we can vaccinate the world by the end of next year and build back better from coronavirus,” said Johnson in a statement, as reported by AP News.

Source: BioSpace

Likewise, French President Emmanuel Macron noted that France would share at least 30 million of its COVID-19 vaccines by the end of 2021.

For its part in the global vaccine-sharing effort, the U.S. plans to purchase and distribute 500 million doses of Pfizer/BioNTech’s mRNA COVID-19 vaccine. The distribution will be accomplished through the global COVAX alliance and will go toward 92 lower-income nations as well as the African Union. 

According to Biden, the vaccine doses will be shipped to these countries in August, with up to 200 million distributed across the globe by 2021’s end. The other 300 million vaccine doses will be distributed in the first half of next year. As such, the U.S. represents COVAX’s largest vaccine donor and single largest funder set at a $4 billion pledge.

The vaccine-sharing commitment by the G7 leaders is welcome news, considering the global COVAX alliance experienced a slow start to its inoculation campaign. 

To date, the alliance has distributed approximately 81 million vaccine doses across the world, but parts of Africa and other regions have largely been unable to gain access to these doses. Only France has so far started shipping its vaccines through the COVAX alliance. 

On Thursday, Biden said that a part of the 80 million doses the country had committed to donation were already being distributed. Additionally, the U.S. has provided Mexico and Canada a few million COVID-19 vaccines.

 
BioSpace source:
 
 
 

Read More

Continue Reading

Trending